Microbot Medical Inc. (Nasdaq: MBOT) today announced the closing of its previously announced registered direct offering priced at-the-market under Nasdaq rules for the purchase and sale of 6,103,289 ...

In a report released on February 7, Heiko Ihle from H.C. Wainwright reiterated a Buy rating on UR-Energy (URG – Research Report), with a price ...

The company posted quarterly adjusted earnings of $3.48 per share which missed the analyst consensus estimate of $4.03 per ...

H.C. Wainwright reaffirmed a Buy rating and a $38.00 price target for Palvella Therapeutics (NASDAQ: PVLA) shares. Currently trading at $15.72, the stock has shown strong momentum with a 31% gain year ...

H.C. Wainwright increased its price target on Corcept Therapeutics (NASDAQ:CORT) shares to $115 from the previous $80, while ...

H.C. Wainwright raised the firm’s price target on NextTrip (NTRP) to $5 from $2.50 and keeps a Neutral rating on the shares after the company ...

HC Wainwright reaffirmed their buy rating on shares of Corbus Pharmaceuticals (NASDAQ:CRBP – Free Report) in a research ...

HC Wainwright reissued their buy rating on shares of Immix Biopharma (NASDAQ:IMMX – Free Report) in a report released on ...

The gross proceeds from the offering, before deducting the placement agent's fees and other offering expenses payable by the Company, were approximately $8 million. Mustang intends to use the net ...

Analysts expect the Boston, Massachusetts-based company to report quarterly earnings at $4.02 per share, down from $4.20 per share in the year-ago period. Vertex Pharmaceuticals projects quarterly ...